Semliki Forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity

RNA replicons offer a number of qualities which make them attractive as vaccination vectors. Both alphavirus and flavivirus replicon vaccines have been investigated in preclinical models yet there has been little direct comparison of the two vector systems. To determine whether differences in the bi...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 23; no. 33; pp. 4189 - 4194
Main Authors Tannis, Laura Lee, Gauthier, Andree, Evelegh, Carole, Parsons, Robin, Nyholt, Dana, Khromykh, Alexander, Bramson, Jonathan L.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 21.07.2005
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:RNA replicons offer a number of qualities which make them attractive as vaccination vectors. Both alphavirus and flavivirus replicon vaccines have been investigated in preclinical models yet there has been little direct comparison of the two vector systems. To determine whether differences in the biology of the two vectors influence immunogenicity, we compared two prototypic replicon vectors based on Semliki Forest virus (SFV) (alphavirus) and Kunjin virus (KUN) (flavivirus). Both vectors when delivered as naked RNAs elicited comparable CD8+ T cell responses but the SFV vectors elicited greater humoral responses to an encoded cytoplasmic antigen β-galactosidase. Studies in MHC class II-deficient mice revealed that neither vector could overcome the dependence of CD4+ T cell help in the development of humoral and cellular responses following immunization. These studies indicate that the distinct biology of the two replicon systems may differentially impact the adaptive immune response and this may need to be considered when designing vaccination strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.04.005